Halozyme Therapeutics Inc. Common Stock (HALO)

About HALO

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as wel…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

423

Website

www.halozyme.com/

Fundamentals

1-day range

$104.7$106.81

Market cap

$9.76B

P/E (trailing)

27.63

P/E (forward)

10.14

EPS (trailing)

$3.35

Dividend yield

—

Beta

0.90

Avg. volume

2.01M

Forecasts

9 analyst ratings

Halozyme Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• HALO

  Halozyme Therapeutics Inc. Common Stock

  $105.33

  ▼ 1.49%
  Market cap $9.76BP/E 27.63
  $61.23$109.66
• QGEN

  Qiagen N.V. Common Shares

  $43.12

  ▼ 1.43%
  Market cap $8.72BP/E 22.14
  $32.53$57.82
• KYMR

  Kymera Therapeutics Inc. Common Stock

  $118.08

  ▼ 1.79%
  Market cap $8.25BP/E —
  $39.84$130.05
• CRSP

  CRISPR Therapeutics AG Common Shares

  $57.69

  ▼ 2.84%
  Market cap $4.78BP/E —
  $44.12$78.48
• ADPT

  Adaptive Biotechnologies Corporation Common Stock

  $25.19

  ▼ 4.73%
  Market cap $3.70BP/E —
  $12$26.87
• RLAY

  Relay Therapeutics Inc. Common Stock

  $18.78

  ▼ 3.30%
  Market cap $3.60BP/E —
  $3.5$21.27
• BEAM

  Beam Therapeutics Inc. Common Stock

  $29.31

  ▼ 3.84%
  Market cap $2.67BP/E —
  $16.02$38.26

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Watching Halozyme Therapeutics; Hearing Investor Business Daily SwingTrader Sells Stock
  benzinga · 8/25/2026

Institutional Ownership

March 31, 2026

Total shares held

113.86M

Total value held

$7.04B

Institutional holders

622